Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia

Author:

Palma Medina Laura M.,Babačić Haris,Dzidic Majda,Parke Åsa,Garcia Marina,Maleki Kimia T.,Unge Christian,Lourda Magda,Kvedaraite Egle,Chen Puran,Muvva Jagadeeswara Rao,Cornillet Martin,Emgård Johanna,Moll Kirsten,Michaëlsson Jakob,Flodström-Tullberg Malin,Brighenti Susanna,Buggert Marcus,Mjösberg Jenny,Malmberg Karl-Johan,Sandberg Johan K.,Gredmark-Russ Sara,Rooyackers Olav,Svensson Mattias,Chambers Benedict J.,Eriksson Lars I.,Pernemalm Maria,Björkström Niklas K.,Aleman Soo,Ljunggren Hans-Gustaf,Klingström Jonas,Strålin Kristoffer,Norrby-Teglund Anna,

Abstract

AbstractBackgroundCOVID-19 remains a major public health challenge, requiring the development of tools to improve diagnosis and inform therapeutic decisions. As dysregulated inflammation and coagulation responses have been implicated in the pathophysiology of COVID-19 and sepsis, we studied their plasma proteome profiles to delineate similarities from specific features.MethodsWe measured 276 plasma proteins involved in Inflammation, organ damage, immune response and coagulation in healthy controls, COVID-19 patients during acute and convalescence phase, and sepsis patients; the latter included (i) community-acquired pneumonia (CAP) caused by Influenza, (ii) bacterial CAP, (iii) non-pneumonia sepsis, and (iv) septic shock patients.ResultsWe identified a core response to infection consisting of 42 proteins altered in both COVID-19 and sepsis, although higher levels of cytokine storm-associated proteins were evident in sepsis. Furthermore, microbiologic etiology and clinical endotypes were linked to unique signatures. Finally, through machine learning, we identified biomarkers, such as TRIM21, PTN and CASP8, that accurately differentiated COVID-19 from CAP-sepsis with higher accuracy than standard clinical markers.ConclusionsThis study extends the understanding of host responses underlying sepsis and COVID-19, indicating varying disease mechanisms with unique signatures. These diagnostic and severity signatures are candidates for the development of personalized management of COVID-19 and sepsis.

Funder

Svenska Sällskapet för Medicinsk Forskning

Barncancerfonden

Vetenskapsrådet

Cancerfonden

Nordstjernan

Knut och Alice Wallenbergs Stiftelse

Center for Innovative Medicine

VINNOVA

Stockholm läns landsting

Karolinska Institute

Publisher

Springer Science and Business Media LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3